Aldurazyme® (laronidase)

Aldurazyme (laronidase) is covered only for MPS I patients with Hurler or Hurler–Scheie phenotypes and for Scheie patients with moderate-to-severe symptoms, and is not covered for other diagnoses or mild/asymptomatic Scheie. Coverage requires confirmed diagnosis by deficient α-L-iduronidase activity or molecular genetic testing, prescription/consultation by a geneticist/endocrinologist/metabolic/lysosomal disorder specialist, adherence to 0.58 mg/kg IV weekly dosing, documentation of symptom severity, and is authorized for up to 12 months subject to safety criteria.

"Aldurazyme (laronidase) is indicated for the treatment of individuals with the Hurler or Hurler-Scheie forms of mucopolysaccharidosis type I."

Sign up to see full coverage criteria, indications, and limitations.